{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443918312
| IUPAC_name = (1S,3aS,3bR,10aR,10bS,12aS)-1,10a,12a-Trimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
| image = Hydroxystenozole.png
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 5697-57-4
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 238684
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 208502
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5OW19U0553
| KEGG = 
| ChEBI = 79555
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2105010

<!--Chemical data-->
| C=21 | H=30 | N=2 | O=1
| molecular_weight = 326.48 g/mol
| SMILES = C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC5=C(C[C@]34C)C=NN5
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C21H30N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h10,12,15-17,24H,4-9,11H2,1-3H3,(H,22,23)/t15-,16+,17+,19+,20+,21+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = OIIHTRLQCQVVQC-OBQKJFGGSA-N
| synonyms = NSC-43194; 17α-Methyl-2'H-androsta-2,4-dieno[3,2-c]pyrazol-17β-ol; 17β-Hydroxy-17α-methylandrost-4-eno[3,2-c]-pyrazole
}}

'''Hydroxystenozole''' ([[International Nonproprietary Name|INN]]), also known as '''17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol''', is an [[oral administration|orally active]] [[anabolic-androgenic steroid]] (AAS) and a [[17α-alkylated anabolic steroid|17α-alkylated]] [[chemical derivative|derivative]] of [[testosterone]] that was described in the literature in 1967 but was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA668|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|page=668}}</ref> It is closely related to [[stanozolol]] (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only in [[hydrogenation]] (i.e., [[double bond]]s and their placement).

==References==
{{Reflist|2}}


{{Androgen receptor modulators}}

[[Category:Androgens and anabolic steroids]]
[[Category:Androstanes]]
[[Category:Pyrazoles]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}